Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement

DOI Web Site 2 Citations
  • Matthew I. Milowsky
    Matthew I. Milowsky, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Christopher M. Booth, Queen’s University, Kingston; Libni J. Eapen, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Timothy Gilligan, Cleveland Clinic, Cleveland, OH; Ralph J. Hauke, Nebraska Cancer Specialists, Omaha, NE; Pat Boumansour, Patient Representative, Palm Coast, FL; and Cheryl T. Lee, University of Michigan,...
  • R. Bryan Rumble
    Matthew I. Milowsky, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Christopher M. Booth, Queen’s University, Kingston; Libni J. Eapen, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Timothy Gilligan, Cleveland Clinic, Cleveland, OH; Ralph J. Hauke, Nebraska Cancer Specialists, Omaha, NE; Pat Boumansour, Patient Representative, Palm Coast, FL; and Cheryl T. Lee, University of Michigan,...
  • Christopher M. Booth
    Matthew I. Milowsky, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Christopher M. Booth, Queen’s University, Kingston; Libni J. Eapen, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Timothy Gilligan, Cleveland Clinic, Cleveland, OH; Ralph J. Hauke, Nebraska Cancer Specialists, Omaha, NE; Pat Boumansour, Patient Representative, Palm Coast, FL; and Cheryl T. Lee, University of Michigan,...
  • Timothy Gilligan
    Matthew I. Milowsky, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Christopher M. Booth, Queen’s University, Kingston; Libni J. Eapen, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Timothy Gilligan, Cleveland Clinic, Cleveland, OH; Ralph J. Hauke, Nebraska Cancer Specialists, Omaha, NE; Pat Boumansour, Patient Representative, Palm Coast, FL; and Cheryl T. Lee, University of Michigan,...
  • Libni J. Eapen
    Matthew I. Milowsky, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Christopher M. Booth, Queen’s University, Kingston; Libni J. Eapen, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Timothy Gilligan, Cleveland Clinic, Cleveland, OH; Ralph J. Hauke, Nebraska Cancer Specialists, Omaha, NE; Pat Boumansour, Patient Representative, Palm Coast, FL; and Cheryl T. Lee, University of Michigan,...
  • Ralph J. Hauke
    Matthew I. Milowsky, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Christopher M. Booth, Queen’s University, Kingston; Libni J. Eapen, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Timothy Gilligan, Cleveland Clinic, Cleveland, OH; Ralph J. Hauke, Nebraska Cancer Specialists, Omaha, NE; Pat Boumansour, Patient Representative, Palm Coast, FL; and Cheryl T. Lee, University of Michigan,...
  • Pat Boumansour
    Matthew I. Milowsky, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Christopher M. Booth, Queen’s University, Kingston; Libni J. Eapen, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Timothy Gilligan, Cleveland Clinic, Cleveland, OH; Ralph J. Hauke, Nebraska Cancer Specialists, Omaha, NE; Pat Boumansour, Patient Representative, Palm Coast, FL; and Cheryl T. Lee, University of Michigan,...
  • Cheryl T. Lee
    Matthew I. Milowsky, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Christopher M. Booth, Queen’s University, Kingston; Libni J. Eapen, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Timothy Gilligan, Cleveland Clinic, Cleveland, OH; Ralph J. Hauke, Nebraska Cancer Specialists, Omaha, NE; Pat Boumansour, Patient Representative, Palm Coast, FL; and Cheryl T. Lee, University of Michigan,...

Abstract

<jats:sec><jats:title>Purpose</jats:title><jats:p> To endorse the European Association of Urology guideline on muscle-invasive (MIBC) and metastatic bladder cancer. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. </jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p> The guideline on MIBC and metastatic bladder cancer was reviewed for developmental rigor by methodologists. The ASCO Endorsement Panel then reviewed the content and recommendations. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> The ASCO Endorsement Panel determined that the recommendations from the European Association of Urology guideline on MIBC and metastatic bladder cancer, published online in March 2015, are clear, thorough, and based on the most relevant scientific evidence. ASCO endorses the guideline on MIBC and metastatic bladder cancer and has added qualifying statements, including highlighting the use of chemoradiotherapy for select patients with MIBC and recommending a preference for clinical trials in the treatment of metastatic disease in the second-line setting. </jats:p></jats:sec><jats:sec><jats:title>Recommendations</jats:title><jats:p> Multidisciplinary care for patients with MIBC and metastatic bladder cancer is critical. The standard treatment of MIBC (cT2-T4a N0M0) is neoadjuvant cisplatin-based combination chemotherapy followed by radical cystectomy. In cisplatin-ineligible patients, radical cystectomy alone is recommended. Adjuvant cisplatin-based chemotherapy may be offered to high-risk patients who have not received neoadjuvant therapy. Chemoradiotherapy may be offered as an alternative to cystectomy in appropriately selected patients with MIBC and in some patients for whom cystectomy is not an option. Metastatic disease should be treated with cisplatin-containing combination chemotherapy or with carboplatin combination chemotherapy or single agents in patients ineligible for cisplatin. Additional information is available at http://www.asco.org/endorsements/MIBC and www.asco.org/guidelineswiki . </jats:p></jats:sec>

Journal

Citations (2)*help

See more

Details 詳細情報について

Report a problem

Back to top